Novo Holdings-backed Antag raises $84M series A to send complementary obesity candidate to the clinic zbecker Tue, 12/03/2024 - 16:17.: Antag Therapeutics thinks its glucose dependent insulinotropic polypeptide receptor (GIPR) antagonist could carve out a space in the buzzy obesity market as a complementary treatment, a sentiment now backed by €80 million euros ($84 million) from a series A financing. Versant Ventures led the fundraising round, with founding investor Novo Holdings and SR One, Dawn Biopharma, Pictet, Longview Ventures and the Export and Investment Fund of Denmark all in tow, according to a Dec. 4 release.